Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EBITDA: 2016-2025

Historic EBITDA for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $29.4 million.

  • Tg Therapeutics' EBITDA rose 136.17% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 20452.28%. This contributed to the annual value of $41.9 million for FY2024, which is 103.21% up from last year.
  • Per Tg Therapeutics' latest filing, its EBITDA stood at $29.4 million for Q3 2025, which was down 15.72% from $34.8 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' EBITDA ranged from a high of $114.8 million in Q3 2023 and a low of -$92.9 million during Q4 2021.
  • In the last 3 years, Tg Therapeutics' EBITDA had a median value of $8.8 million in 2024 and averaged $12.3 million.
  • Per our database at Business Quant, Tg Therapeutics' EBITDA soared by 428.30% in 2023 and then plummeted by 89.17% in 2024.
  • Quarterly analysis of 5 years shows Tg Therapeutics' EBITDA stood at -$92.9 million in 2021, then grew by 16.58% to -$77.5 million in 2022, then spiked by 83.90% to -$12.5 million in 2023, then soared by 339.88% to $29.9 million in 2024, then skyrocketed by 136.17% to $29.4 million in 2025.
  • Its EBITDA was $29.4 million in Q3 2025, compared to $34.8 million in Q2 2025 and $8.6 million in Q1 2025.